340B Drug Pricing Program
The 340B Drug Pricing Program 鈥渉as enabled hospitals and health systems to support and expand access and services consistent with their mission and the program鈥檚 original and ongoing charge,鈥 the AHA and Association of American Medical Colleges today told leaders of the House Energy and Commerce鈥
Two hundred twenty-eight members of the House of Representatives yesterday urged the Centers for Medicare & Medicaid Services to abandon its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program.
The Health Resources and Services Administration today delayed to July 1, 2018 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers. 鈥淲e are delaying the effective date of the Jan.
A bipartisan group of 228 House lawmakers yesterday urged the Centers for Medicare & Medicaid Services (CMS) to abandon its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program.
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription drug costs. Despite significant oversight from HRSA and the program鈥檚 proven record of decreasing government spending and expanding access to鈥
Sens. John Thune (R-SD), Rob Portman (R-OH), Shelley Moore Capito (R-WV), Debbie Stabenow (D-MI), Tammy Baldwin (D-WI) and Bill Nelson (D-FL) are collecting signatures on a "Dear Colleague" letter urging the CMS to rescind its proposal to reduce Medicare Part B payment for drugs acquired through鈥
The AHA today urged the Health Resources and Services Administration to implement its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers without delay. 鈥淒elaying the implementation of the ceiling price and CMPs an additional nine months 鈥 from Oct. 1,鈥
The Centers for Medicare & Medicaid Services (CMS) should withdraw its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program, AHA yesterday told the agency in comments on its outpatient prospective payment system proposed rule for calendar year 2018鈥